Cadila Healthcare: A pain reliever
Focus on the high-margin products and launches lined up in the US are key drivers15-09-2018
15-09-2018
Zydus Cadila gets USFDA nod to market osteoporosis drug
Drug firm Zydus Cadila has received a final nod from the US health regulator for Risedronate Sodium delayed-release tablets, used for the treatment o13-09-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Risedronate Sodium Delayed-Release Tablets13-09-2018
Company news: Zydus Cadila
Zydus Cadila has received tentative approval from the United States Food and Drug Administration (USFDA) for Sitagliptin tablets for sale in the US11-09-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Sitagliptin Tablets11-09-2018
Zydus Cadila gets USFDA nod for antiviral drug
Zydus Cadila has received final approval from the US health regulator to market Acyclovir injection, used to treat infections caused by herpes virus,05-09-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Acyclovir Sodium Injection05-09-2018
Zydus Cadila gets USFDA nod to market 2 products
Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market Gemfibrozil tablets and Aripiprazole orally d30-08-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for two products, Gemfibrozil Tablets USP and Aripiprazole Orally Disintegrating Tablets USP30-08-2018
Cadila gets 5 observations from USFDA
Cadila Healthcare has received five observations from USFDA after the inspection of Liva Pharmaceuticals' injectables manufacturing facility. Liva is29-08-2018